

New-Onset Palmar Psoriasis Following mRNA COVID-19 Vaccination: A Case Report

Haya Fahad A Alzamami¹, Omer A AlSulaiman¹, Gaeda Khaled I Alkaltham², Hadeel K Alotaibi³

¹Department of Dermatology, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia; ²Department of Dermatology, Ministry of Health, Dammam, Saudi Arabia; ³College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia

Correspondence: Hadeel K Alotaibi, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, P.O. Box 34224, Saudi Arabia, Tel +966555197355, Email hadeellkhaled@gmail.com

Abstract: Palmoplantar psoriasis is a rare, chronic, localized variant of psoriasis. It represents 3–4% of all psoriasis cases and is characterized by hyperkeratotic or desquamative erythematous plaques with fissures and erosions exhibiting acral distribution. Occasionally, superimposed sterile pustulations may also occur. New-onset psoriasis and various clinical subtypes of psoriasis exacerbation have been reported following the administration of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines, with plaque-type psoriasis being the most common. However, palmar psoriasis has not yet been reported in association with COVID-19 vaccination. Herein, we present a case of new-onset palmar psoriasis along with nail changes following mRNA COVID-19 vaccination, which was further exacerbated following successive vaccine doses.

Keywords: psoriasis, palmoplantar, mRNA vaccine, COVID-19

Introduction

Palmoplantar psoriasis is an atypical variant of psoriasis that mainly affects the palmar and plantar skin and represents 3–4% of all psoriasis cases.¹ Its major clinical presentation consists of sharply demarcated hyperkeratotic or desquamative erythematous plaques, along with fissures and erosions, with an acral distribution. Superimposed sterile pustulation may also occur occasionally. These lesions are often painful and contribute to more significant physical discomfort and functional impairment compared to psoriasis affecting other body regions.² Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination has been the main public health measure used to overcome the coronavirus disease 2019 (COVID-19) pandemic. However, similarly to certain other drugs and vaccines, new-onset and exacerbation of psoriasis have been reported following the administration of COVID-19 vaccines.^{3–22} One systematic review showed that the exacerbation of pre-existing psoriasis is more common than *de novo* psoriasis following COVID-19 vaccination, as only 15.1% of reported cases were ones of new-onset psoriasis. Among the several clinical subtypes of psoriasis, plaque psoriasis was the most reported following COVID-19 vaccination (33.3%), followed by guttate (25.9%), pustular (14.8%), nail (11.1%), and annular psoriasis 3.7%.²³ To our knowledge, isolated palmar psoriasis accompanied by psoriatic fingernail changes has not yet been reported in the literature following COVID-19 vaccination. Herein, we present a case of new-onset palmar psoriasis accompanied by psoriatic nail changes following messenger ribonucleic acid (mRNA)-based COVID-19 vaccination, which was exacerbated by subsequent vaccine doses.

Case Presentation

A 51-year-old married woman, non-smoker, taking no regular medications other than intermittent paracetamol for headaches and with no notable prior medical history, presented to our dermatology outpatient clinic complaining of bilateral palmar skin eruption that had been ongoing for 3 years. The patient denied any family history of atopic dermatitis, psoriasis, or other autoimmune diseases. She was not receiving any medications, her weight was 68 kg, height 162 cm, and body mass index was 25.9 kg/m². She reported being in a normal state of health until 3 years prior, when she received her first dose of the Pfizer-BioNTech mRNA-based

COVID-19 vaccine, after which she began developing painless, mildly pruritic, fluid-filled lesions that drained upon rupture, followed by desquamation. These lesions were discretely scattered over both palms and were well managed with topical corticosteroids.

The patient received a second dose of the same vaccine, and 3 days later, she noticed a significant exacerbation of the condition. The vesicular skin eruption disseminated until it involved both of her palms entirely, followed by severe skin desquamation. She also noticed related changes involving her fingernails. Following this, her condition had begun responding poorly to topical corticosteroids, without complete remission. No specific diagnosis had yet been made.

The condition then began to disrupt the patient's lifestyle, making daily life tasks more challenging. She noted that she had a prior history of mild atopic dermatitis during childhood, but no other personal or family history of psoriasis. No psoriatic skin lesions had occurred elsewhere apart from her palms. The patient had no history of joint pain, drug intake that could have triggered the condition, allergen or irritant exposure, or animal contact. The patient worked as a secretary in an office, occupying a desk-based workspace.

Dermatological examination revealed scaly erythematous plaques with bilateral desquamation and erosions involving the bilateral palmar skin extending to the dorsal aspects of the fingers. In addition to fingernail changes, which included irregular nail-pitting, distal onycholysis and salmon patches were also observed. No psoriatic skin changes were observed upon full skin examination (Figures 1 and 2).

Histopathological examination of a skin punch biopsy specimen revealed that the epidermis had areas of parakeratosis in the stratum corneum. The granular layer was intact, with regular acanthosis and moderate spongiosis. The dermis showed perivascular mixed lympho-histiocytic inflammatory infiltrates involving the upper, middle, and lower dermis, whereas the hypodermis was unremarkable. Grocott's methenamine silver and periodic acid-Schiff staining did not reveal any evidence of fungal elements. The clinical and histopathological findings suggested spongiotic psoriasiform dermatitis. Given the extensive palmar involvement, associated nail changes, functional impairment, inadequate response to topical therapy, and supportive histopathological findings, treatment with ixekizumab was initiated. Baseline investigations, including complete blood count, liver and renal function tests, tuberculosis screening, and hepatitis B and C serologies, were all within normal limits. A loading dose of 160 mg was administered subcutaneously at week 0, followed by 80 mg every two weeks for 12 weeks, and subsequently 80 mg every 4 weeks as maintenance. By week 5, the patient showed significant reduction in erythema, desquamation, and pruritus. Complete resolution and remission were achieved after 8 weeks of treatment (Figure 3). The



Figure 1 Well-defined scaly erythematous plaques with desquamation and erosions are observed on the bilateral palmar skin.



Figure 2 Desquamation extended to the dorsal aspect of the fingers, along with fingernail changes including irregular nail pitting, distal onycholysis, and salmon patches.




Figure 3 Marked clinical improvement with resolution of erythema and desquamation. Residual post-inflammatory hyperpigmentation and fine scaling over the central palms, with mild lichenification and accentuation of palmar creases.

patient has been maintained on biweekly ixekizumab injections with regular clinic follow-up for the past 16 months and continues to show sustained clinical improvement without evidence of relapse or treatment-related adverse effects. The patient provided written informed consent for the publication of this case details and accompanying images.

Discussion

Psoriasis is a complex immune-mediated skin disease that leads to chronic inflammation and accelerated skin cell growth in genetically predisposed individuals. Chronic plaque-type psoriasis represents its typical primary clinical manifestation, although other clinical subtypes with unique and independent characteristics have also been observed in clinical practice. One of these subtypes is palmoplantar psoriasis, which is considered a rare variant of psoriasis that mainly affects the skin of the palms and soles, accounting for 3–4% of all psoriasis cases.¹ Palmoplantar psoriasis is often accompanied by psoriatic lesions elsewhere on the body, rarely presenting in isolation. In 59% of cases, both the palms and soles are affected, compared to 21% with palms alone and 20% with soles alone. One study reported that patients with palmoplantar psoriasis have a 91% risk of nail involvement,²⁴ as was observed in our patient.

To date, the pathogenesis of new-onset psoriasis following COVID-19 vaccination remains unclear. However, most current theories on this topic are based on the mechanism of its development following other vaccines such as influenza, Bacillus Calmette-Guérin (BCG), tetanus-diphtheria, and pneumococcal polysaccharide. For example, following vaccinations for influenza, BCG, or tetanus-diphtheria toxoid vaccination, the production of interleukin (IL)-6 increases. Thus, Th17 immune cells become less regulated and proliferate. These cells are particularly implicated in the pathogenesis of psoriasis.²⁵ Elevated Th17 responses have also been observed in patients with severe COVID-19 infection.²⁶ Moreover, BCG and pneumonia vaccination increase IL-2, IL-12, tumor necrosis factor- α , and interferon- γ levels—all of which play major roles in the pathogenesis of psoriasis, by promoting epidermal proliferation and the secretion of IL-8 to activate neutrophil ingression.²⁷

Upon literature review, we identified one case series and 19 case reports describing new-onset psoriasis following COVID-19 vaccination, summarized in Table 1. Among the cases included in our literature review, females were slightly more affected than males, with a mean age of approximately 53 years. Among the reported subtypes of psoriasis, plaque

Table 1 Summary of Reported Cases of New-Onset Psoriasis Following COVID-19 Vaccination

Reference	Patients (n)	Sex/Age	Type of Psoriasis	Vaccine Type	Dose	Days of Onset	Treatment
Tran et al ³	3	Pt1: Male/ 51 Pt2: Female/ 68 Pt3: Male/ 73	Pt1: Plaque Pt2: Plaque Pt3: Guttate	Pt1: Oxford-AstraZeneca AZD122 Pt2: Pfizer/BioNTech BNT162b2 Pt3: Pfizer/BioNTech BNT162b2	Pt1: 3 Pt2: 3 Pt3: 1	Pt1: 7 Pt2: 30 Pt3: 30	Calcipotriol/ Betamethasone + Antihistamines
Gargiulo et al ⁴	2	Pt1: Female/ 82 Pt2: Male/ 29	N1: Plaque N2: Pustular	Pt1: Pfizer/BioNTech BNT162b2 Pt2: Pfizer/BioNTech BNT162b2	Pt1: 3 Pt2: 2	N/A	Pt1: Secukinumab Pt2: Guselkumab
Nagrani et al ⁵	2	Pt1: Female/ 56 Pt2: Male/ 65	Pt1: Plaque Pt2: Plaque	Pt1: Oxford-AstraZeneca AZD122 Pt2: Oxford-AstraZeneca AZD122	Pt1: 1,2 Pt2: 2	Pt1: 7,2 Pt2: 10	Emollients + Apremilast + Antihistamines
Ouni et al ⁶	2	Pt1: Male/ 59 Pt2: Female/ 23	Pt1: Guttate Pt2: Guttate	Pt1: Pfizer/BioNTech BNT162b Pt2: Janssen COVID 19 vaccine, Ad26.COV2.S	Pt1: 1,2,3 Pt2: 1	Pt1: 7 Pt2: 2	Topical corticosteroid
Wei et al ⁷	1	Male/ 24	Plaque	The Moderna mRNA-1273	2	24	Ixekizumab + Acitretin 25 mg
Cortonesi et al ⁸	1	Female/ 82	Plaque	Pfizer/BioNTech BNT162b	1	7	Ixekizuma
Ständer et al ⁹	1	Female/ 50	Plaque	Pfizer-BioNTech BNT162b2	2	7	Topical betamethasone/ calcipotriol; methotrexate 15 mg/ week
Magro et al ¹⁰	1	Male/ 58	Guttate	Pfizer-BioNTech BNT162b2	N/A	14	N/A
Song et al ¹¹	1	Female/ 23	Guttate	Pfizer/BioNTech BNT162b	1	2	Calcipotriol/ Betamethasone

(Continued)

Table 1 (Continued).

Reference	Patients (n)	Sex/Age	Type of Psoriasis	Vaccine Type	Dose	Days of Onset	Treatment
Lehmann et al ¹²	1	Female/ 79	Guttate	Pfizer/BioNTech BNT162b	1	10	Calcipotriol/ Betamethasone + NBUVB
Pesqué et al ¹³	1	Male/ 72	Guttate	The Moderna mRNA-1273	2	6	Calcipotriol/ Betamethasone
El Mashaari et al ¹⁴	2	Females/ N/A	Palmoplantar pustulosis	Pt1: Pfizer/BioNetch BNT162b Pt2: Sinopharm [Vero Cell]-Inactivated COVID-19 vaccine	N/A	Pt1: 7 Pt2: 14	Pt1: Guselkumab 100 mg (0, 4, then every 8 weeks). Pt2: Calcipotriol/ Betamethasone
Hsu & Tsai ¹⁵	1	Female/ 54	Palmoplantar pustulosis	Pfizer/BioNTech BNT162b	2	14	Ixekizumab (160 mg then 80 mg biweekly); cyclosporine on flare
Elamin et al ¹⁶	1	Female/ 66	Generalized pustular	Oxford-AstraZeneca AZD122	1	21	Acitretin 25 mg
Frioui et al ¹⁷	1	Male/ 20	Generalized pustular	Pfizer/BioNTech BNT162b	1	4	Topical corticosteroid + Acitretin 25 mg
Romagnuolo et al ¹⁸	1	Female/ 64	Annular pustular	Pfizer/BioNTech BNT162b	1	N/A	Methotrexate 15 mg/week
Lamberti et al ¹⁹	1	Female/ 45	Nail	Pfizer/BioNTech BNT162b	2	3	N/A
Ricardo et al ²⁰	1	Female/ 76	Nail	Pfizer/BioNTech BNT162b	2	7	Topical corticosteroid
Ruggiero et al ²¹	1	Female/ 47	Nail	Pfizer/BioNTech BNT162b	2	17	Ixekizuma
Chhabra et al ²²	1	Male/ N/A	Annular plaque	Oxford-AstraZeneca AZD122	1	14	N/A

Abbreviations: Pt: Patient, N/A: Not available.

psoriasis was the most common, followed by guttate, pustular, nail, and annular psoriasis. Pfizer-BioNTech was the most common COVID-19 vaccine type linked to new-onset psoriasis, followed by AstraZeneca, Moderna, and Janssen. Furthermore, psoriasis has been reported to develop following the first, second, and third vaccine doses, with some patients developing the condition after every dose. The mean time to onset of *de novo* psoriasis following vaccine administration has been reported to be ~10 days. Most patients showed good responses to topical treatments, although some of them required treatment with conventional systemic medications and biologics. Unfortunately, palmoplantar psoriasis is often resistant to many topical and systemic therapies, meaning that many patients eventually require biologics-based therapies.²

Treatment of moderate-to-severe palmoplantar psoriasis includes acitretin, phototherapy, and traditional immunosuppressive drugs. However, the majority of patients eventually transition to biological therapy because of the adverse effects of conventional systemic treatments. As the pathogenesis of palmoplantar psoriasis involves overproduction of the pro-inflammatory cytokines IL-17 and IL-23, recent therapeutic advances have targeted this pathway using biologic agents that inhibit IL-17 and IL-23, yielding promising outcomes. A previous retrospective study comparing the effectiveness of IL-17 and IL-23 inhibitors in treating palmoplantar psoriasis found no significant difference between them.²⁸ In our case, we used ixekizumab, a monoclonal antibody that inhibits IL-17. The loading dose is 160 mg subcutaneously, followed by 80 mg every 2 or 4 weeks. Clinical trials have demonstrated strong efficacy, with up to 89% of patients achieving PASI75 and 70% achieving PASI90 at 12 weeks. Long-term studies confirm a sustained response, with over 80% maintaining PASI75 after 3 years. The safety profile is acceptable, with common adverse effects including mild infections, nasopharyngitis, and injection site reactions. However, caution is advised in patients with a history of inflammatory bowel disease because of the risk of potential exacerbation.²⁹

Conclusion

This case report presents new-onset palmar psoriasis following mRNA-based COVID-19 vaccination, which was successfully managed with ixekizumab. To date, cases of palmar psoriasis have been rare in the literature. Given the importance of the COVID-19 vaccine in terms of controlling the spread of SARS-CoV-2 infection, recognizing even rare types of psoriasis as adverse events connected to these vaccines is crucial for timely diagnosis and management.

Abbreviations

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), Bacillus Calmette-Guérin (BCG), messenger ribonucleic acid (mRNA), interleukin (IL).

Ethical Approval

The study was approved by Imam Abdulrahman Bin Faisal University Institutional Review Board on June 9, 2024 (IRB-2024-01-467), and we confirm that institutional approval was required for publication of this case details.

Acknowledgments

The authors thank the patient for agreeing to the publication of her medical information in this report.

Funding

There is no funding to report.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ferreli C, Pinna AL, Piloni L, Tomasini CF, Rongioletti F. Histopathological aspects of psoriasis and its uncommon variants. *G Ital Dermatol Venereol.* 2018;153(2):173–184. doi:10.23736/S0392-0488.17.05839-4
2. Sanchez IM, Sorenson E, Levin E, Liao W. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. *Dermatol Ther.* 2017;7(4):425–446. doi:10.1007/s13555-017-0207-0
3. Tran TNA, Nguyen TTP, Pham NN, Pham NTU, Vu TTP, Nguyen HT. New onset of psoriasis following COVID –19 vaccination. *Dermatol Ther.* 2022;35(8):e15590. doi:10.1111/dth.15590
4. Gargiulo L, Ibba L, Vignoli CA, et al. New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series. *J Dermatol Treat.* 2023;34(1):2198050. doi:10.1080/09546634.2023.2198050
5. Nagrani P, Jindal R, Goyal D. Onset/flare of psoriasis following the ChAdOx1 nCoV-19 corona virus vaccine (oxford-astrazeneca/covishield): report of two cases. *Dermatol Ther.* 2021;34(5):e15085. doi:10.1111/dth.15085
6. Ouni N, Korbi M, Chahed F, et al. New-onset guttate psoriasis following coronavirus disease 2019 vaccination: about two cases. *Dermatol Ther.* 2022;35(8):e15617. doi:10.1111/dth.15617
7. Wei N, Kresch M, Elbogen E, Lebwohl M. New onset and exacerbation of psoriasis after COVID-19 vaccination. *JAAD Case Rep.* 2022;19:74–77. doi:10.1016/j.jcdr.2021.11.016
8. Cortonesi G, Orsini C, Rubegni P, Trovato E. New-onset psoriasis after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine successfully treated with ixekizumab. *Dermatol Ther.* 2022;35(8):e15606. doi:10.1111/dth.15606
9. Ständer S, Zirpel H, Bujoreanu F, Tatu AL, Ludwig RJ, Thaçi D. Clinical features of COVID-19 vaccine-induced exacerbation of psoriasis—A case series and mini review. *Front Med Lausanne.* 2022;9:995150. doi:10.3389/fmed.2022.995150
10. Magro C, Crowson AN, Franks L, Schaffer PR, Whelan P, Nuovo G. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. *Clin Dermatol.* 2021;39(6):966–984. doi:10.1016/j.clindermatol.2021.07.011
11. Song WJ, Lim Y, Jo SJ. De novo guttate psoriasis following coronavirus disease 2019 vaccination. *J Dermatol.* 2022;49(1):e30–e31. doi:10.1111/1346-8138.16203
12. Lehmann M, Schorno P, Hunger RE, Heidemeyer K, Feldmeyer L, Yawalkar N. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. *J Eur Acad Dermatol Venereol.* 2021;35(11):e752–e755. doi:10.1111/jdv.17561
13. Pesqué D, Lopez-Trujillo E, Marcantonio O, Giménez-Arnau AM, Pujol RM. New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin? *J Eur Acad Dermatol Venereol.* 2022;36(2):e80–e81. doi:10.1111/jdv.17690
14. El Mashaari RS, Al Ali AS, Abdel Hadi ZM, Sabri MT, Mahmoud AN. COVID-19 vaccine-induced new-onset pustular psoriasis mimicking skin infection of the hand and foot: a report of two cases. *AIMS Allergy Immunol.* 2025;9(2):136–143. doi:10.3934/Allergy.2025010
15. Hsu Y-SO, Tsai T-F. A case of new-onset palmoplantar pustulosis following mRNA COVID-19 vaccination. *Dermatol Sin.* 2023;41(2):127–128. doi:10.4103/ds.DS-D-23-00004
16. Elamin S, Hinds F, Tolland J. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. *Clin Exp Dermatol.* 2022;47(1):153–155. doi:10.1111/ced.14895

17. Frioui R, Chamli A, Zaouak A, et al. A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine. *Dermatol Ther.* **2022**;35(6):e15444. doi:10.1111/dth.15444
18. Romagnuolo M, Pontini P, Muratori S, Marzano AV, Moltrasio C. De novo annular pustular psoriasis following mRNA COVID-19 vaccine. *J Eur Acad Dermatol Venereol.* **2022**;36(8):e603–e605. doi:10.1111/jdv.18114
19. Lamberti A, Lora V, Graceffa D, Bonifati C, Cota C. Nail psoriasis: a rare mRNA COVID-19 vaccine reaction. *J Eur Acad Dermatol Venereol.* **2022**;36(10):e745–e746. doi:10.1111/jdv.18255
20. Ricardo JW, Lipner SR. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. *JAAD Case Rep.* **2021**;17:18–20. doi:10.1016/j.jdc.2021.09.009
21. Ruggiero A, Potestio L, Battista T, Fabbrocini G, Megna M. Reply to “Nail psoriasis: a rare mRNA COVID-19 vaccine reaction” by Lamberti A et al. *J Eur Acad Dermatol Venereol.* **2023**;37(1):e41–e42. doi:10.1111/jdv.18537
22. Chhabra N, George A. A case of de novo annular-plaque type psoriasis following oxford- astraZeneca COVID-19 vaccination. *Curr Drug Saf.* **2023**;18(4):584–588. doi:10.2174/1574886317666220613163327
23. Potestio L, Battista T, Cacciapuoti S, et al. New onset and exacerbation of psoriasis following COVID-19 vaccination: a review of the current knowledge. *Biomedicines.* **2023**;11(8):2191. doi:10.3390/biomedicines11082191
24. Timotijević ZS, Trajković G, Janković J, et al. How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis. *Postepy Dermatol Alergol.* **2019**;36(5):595–603. doi:10.5114/ada.2019.89508
25. Gunes AT, Fetil E, Akarsu S, Ozbaccivan O, Babayeva L. Possible triggering effect of influenza vaccination on psoriasis. *J Immunol Res.* **2015**;2015:258430. doi:10.1155/2015/258430
26. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. *J Microbiol Immunol Infect.* **2020**;53(3):368–370. doi:10.1016/j.jmii.2020.03.005
27. Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. *Semin Immunopathol.* **2010**;32(1):79–90. doi:10.1007/s00281-009-0191-2
28. Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. *J Dermatol Treat.* **2023**;34(1):2199108. doi:10.1080/09546634.2023.2199108
29. Shelton SK, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: a review of its use for the management of moderate to severe plaque psoriasis. *Annals Pharmacother.* **2019**;53(3):276–284. doi:10.1177/1060028018799982

International Medical Case Reports Journal

Publish your work in this journal

The International Medical Case Reports Journal is an international, peer-reviewed open-access journal publishing original case reports from all medical specialties. Previously unpublished medical posters are also accepted relating to any area of clinical or preclinical science. Submissions should not normally exceed 2,000 words or 4 published pages including figures, diagrams and references. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-medical-case-reports-journal-journal>

Dovepress
Taylor & Francis Group